Spots Global Cancer Trial Database for hematopoietic stem cell transplantation (hsct)
Every month we try and update this database with for hematopoietic stem cell transplantation (hsct) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients | NCT02464098 | Diarrhea | - 18 Years | St. Jude Children's Research Hospital | ||
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05674539 | Acute Myeloid L... Myelodysplastic... Allogeneic Hema... | Fludarabine and... Fludarabine and... | 18 Years - | Wuhan Union Hospital, China | |
| CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | NCT03768310 | Non-hodgkin Lym... Acute Lymphobla... | CD19.CAR-multiV... CD19.CAR-multiV... | 1 Year - 75 Years | Baylor College of Medicine | |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases | NCT05688241 | EBV Lymphoma Post-transplant... | Donor-derived e... | - | University Hospital, Basel, Switzerland | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | NCT01350245 | Acute Myeloid L... Myelodysplastic... Biphenotypic Le... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Plasma Cell Neo... Lymphoma Hodgkin's Disea... Aplastic Anemia | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Mycophenolate M... Tacrolimus Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | NCT00405327 | Sarcoma Neuroblastoma Wilm's Tumor | Tumor lysate-pu... Hematopoietic s... | - 30 Years | University of Michigan Rogel Cancer Center | |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05674539 | Acute Myeloid L... Myelodysplastic... Allogeneic Hema... | Fludarabine and... Fludarabine and... | 18 Years - | Wuhan Union Hospital, China | |
| Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation | NCT00363467 | Acute Myeloid L... | G-CSF Leukapheresis Busulfan Stem cell reinf... | 56 Years - 74 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 | NCT02252107 | Acute Myeloid L... | decitabine | 18 Years - | Radboud University Medical Center | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05674539 | Acute Myeloid L... Myelodysplastic... Allogeneic Hema... | Fludarabine and... Fludarabine and... | 18 Years - | Wuhan Union Hospital, China | |
| CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | NCT03768310 | Non-hodgkin Lym... Acute Lymphobla... | CD19.CAR-multiV... CD19.CAR-multiV... | 1 Year - 75 Years | Baylor College of Medicine | |
| Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation | NCT00363467 | Acute Myeloid L... | G-CSF Leukapheresis Busulfan Stem cell reinf... | 56 Years - 74 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients | NCT01811862 | Multiple Myelom... | Acupuncture Sham acupunctur... | 21 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
